Evidence map›Paper›PMID 31253155›Full record

ArticleDiagnostic pathology2019

Diagnostic terminology used to describe atypia on breast core needle biopsy: correlation with excision and upgrade rates.

Gary Tozbikian, Michael George, Debra L Zynger

Abstract read
In one paragraph

Article in Diagnostic pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gary TozbikianDivision of Breast Pathology, Department of Pathology, Wexner Medical Center at The Ohio State University, E414 Doan Hall, 410 W. 10th Ave, Columbus, OH, 43210, USA. gary.tozbikian@osumc.edu.
Michael GeorgeDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Debra L ZyngerDivision of Genitourinary Pathology, Department of Pathology, The Ohio State University Wexner Medical Center, E401 Doan Hall, 410 W 10th Ave, Columbus, OH, 43210, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubjective qualitative descriptors are sometimes used to describe atypical breast lesions diagnosed on core needle biopsy (CNB) which are limited in extent. In clinical practice, this terminology is used to imply a lower expected risk of upgrade on surgical excision (EXC). It is uncertain how subjective terminology impacts clinical management.

methodsWe conducted a retrospective review of CNB with atypia and compared the EXC and upgrade rates of atypical ductal hyperplasia (ADH) and flat epithelial atypia (FEA) to lesions described as "focal" atypical ductal hyperplasia (FADH), to determine the impact of this diagnostic phrasing on surgical management and risk of malignancy.

resultsFADH and ADH were excised at similar rates (82% vs. 78%). FADH lesions showed a similar upgrade rate (13%) compared to non-focal ADH (10%), and both showed a trend towards higher upgrade and EXC rates compared to FEA. ADH, FADH and FEA all had an upgrade risk that warranted EXC. In non-upgraded EXC, for each diagnostic category we observed similar rates of residual atypia in the EXC.

conclusionsPathologists should avoid the use of qualitative descriptors when describing ADH on CNB because of the potential of this terminology to influence clinical decision making which is unwarranted.

Indexed as

Terminology as TopicAdultAgedBiopsy, Large-Core NeedleBreastBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleHumansMiddle AgedRetrospective StudiesAtypiaAtypical ductal hyperplasiaBiopsyBreastExcisionFlat epithelial atypiaRateUpgrade

Identifiers

PMID31253155
PMCPMC6599335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.